Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

TMPRSS4: A Novel Tumor Prognostic Indicator for the Stratification of Stage IA Tumors and a Liquid Biopsy Biomarker for NSCLC Patients.

Villalba M, Exposito F, Pajares MJ, Sainz C, Redrado M, Remirez A, Wistuba I, Behrens C, Jantus-Lewintre E, Camps C, Montuenga LM, Pio R, Lozano MD, de Andrea C, Calvo A.

J Clin Med. 2019 Dec 3;8(12). pii: E2134. doi: 10.3390/jcm8122134.

2.

Identification of a novel synthetic lethal vulnerability in non-small cell lung cancer by co-targeting TMPRSS4 and DDR1.

Villalba M, Redin E, Exposito F, Pajares MJ, Sainz C, Hervas D, Guruceaga E, Diaz-Lagares A, Cirauqui C, Redrado M, Valencia K, de Andrea C, Jantus-Lewintre E, Camps C, Lopez-Lopez R, Lahoz A, Montuenga L, Pio R, Sandoval J, Calvo A.

Sci Rep. 2019 Oct 28;9(1):15400. doi: 10.1038/s41598-019-51066-3.

3.

Stromal markers of activated tumor associated fibroblasts predict poor survival and are associated with necrosis in non-small cell lung cancer.

Alcaraz J, Carrasco JL, Millares L, Luis IC, Fernández-Porras FJ, Martínez-Romero A, Diaz-Valdivia N, De Cos JS, Rami-Porta R, Seijo L, Ramírez J, Pajares MJ, Reguart N, Barreiro E, Monsó E.

Lung Cancer. 2019 Sep;135:151-160. doi: 10.1016/j.lungcan.2019.07.020. Epub 2019 Jul 24.

4.

YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.

Garmendia I, Pajares MJ, Hermida-Prado F, Ajona D, Bértolo C, Sainz C, Lavín A, Remírez AB, Valencia K, Moreno H, Ferrer I, Behrens C, Cuadrado M, Paz-Ares L, Bustelo XR, Gil-Bazo I, Alameda D, Lecanda F, Calvo A, Felip E, Sánchez-Céspedes M, Wistuba II, Granda-Diaz R, Rodrigo JP, García-Pedrero JM, Pio R, Montuenga LM, Agorreta J.

Am J Respir Crit Care Med. 2019 Oct 1;200(7):888-899. doi: 10.1164/rccm.201807-1292OC.

PMID:
31166114
5.

5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging.

Martínez-Terroba E, Behrens C, Agorreta J, Monsó E, Millares L, Felip E, Rosell R, Ramirez JL, Remirez A, Torre W, Gil-Bazo I, Idoate MA, de-Torres JP, Pio R, Wistuba II, Pajares MJ, Montuenga LM.

Thorax. 2019 Apr;74(4):371-379. doi: 10.1136/thoraxjnl-2018-212194. Epub 2018 Nov 24.

PMID:
30472670
6.

The oncogenic RNA-binding protein SRSF1 regulates LIG1 in non-small cell lung cancer.

Martínez-Terroba E, Ezponda T, Bértolo C, Sainz C, Remírez A, Agorreta J, Garmendia I, Behrens C, Pio R, Wistuba II, Montuenga LM, Pajares MJ.

Lab Invest. 2018 Dec;98(12):1562-1574. doi: 10.1038/s41374-018-0128-2. Epub 2018 Sep 4.

7.

Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer.

Fusco JP, Pita G, Pajares MJ, Andueza MP, Patiño-García A, de-Torres JP, Gurpide A, Zulueta J, Alonso R, Alvarez N, Pio R, Melero I, Sanmamed MF, Rodriguez Ruiz M, Gil-Bazo I, Lopez-Picazo JM, Casanova C, Baz Davila R, Agudo A, Lozano MD, Gonzalez A, Sala N, Ardanaz E, Benitez J, Montuenga L, Gonzalez-Neira A, Perez-Gracia JL.

Cancer Med. 2018 May 15. doi: 10.1002/cam4.1500. [Epub ahead of print]

8.

A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients.

Martínez-Terroba E, Behrens C, de Miguel FJ, Agorreta J, Monsó E, Millares L, Sainz C, Mesa-Guzman M, Pérez-Gracia JL, Lozano MD, Zulueta JJ, Pio R, Wistuba II, Montuenga LM, Pajares MJ.

J Pathol. 2018 Aug;245(4):421-432. doi: 10.1002/path.5096. Epub 2018 Jun 20.

9.

Complement C4d-specific antibodies for the diagnosis of lung cancer.

Ajona D, Okrój M, Pajares MJ, Agorreta J, Lozano MD, Zulueta JJ, Verri C, Roz L, Sozzi G, Pastorino U, Massion PP, Montuenga LM, Blom AM, Pio R.

Oncotarget. 2017 Dec 26;9(5):6346-6355. doi: 10.18632/oncotarget.23690. eCollection 2018 Jan 19.

10.

Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis by CXCL16-mediated Effects.

Ajona D, Zandueta C, Corrales L, Moreno H, Pajares MJ, Ortiz-Espinosa S, Martínez-Terroba E, Perurena N, de Miguel FJ, Jantus-Lewintre E, Camps C, Vicent S, Agorreta J, Montuenga LM, Pio R, Lecanda F.

Am J Respir Crit Care Med. 2018 May 1;197(9):1164-1176. doi: 10.1164/rccm.201703-0660OC.

11.

Erratum to: Telomere shortening and accelerated aging in COPD: findings from the BODE cohort.

Cordoba-Lanus E, Cazorla-Rivero S, Espinoza-Jimenez A, de-Torres JP, Pajares MJ, Aguirre-Jaime A, Celli B, Casanova C.

Respir Res. 2017 Jun 2;18(1):113. doi: 10.1186/s12931-017-0589-7. No abstract available.

12.

Telomere shortening and accelerated aging in COPD: findings from the BODE cohort.

Córdoba-Lanús E, Cazorla-Rivero S, Espinoza-Jiménez A, de-Torres JP, Pajares MJ, Aguirre-Jaime A, Celli B, Casanova C.

Respir Res. 2017 Apr 13;18(1):59. doi: 10.1186/s12931-017-0547-4. Erratum in: Respir Res. 2017 Jun 2;18(1):113.

13.

Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition.

Pereira C, Gimenez-Xavier P, Pros E, Pajares MJ, Moro M, Gomez A, Navarro A, Condom E, Moran S, Gomez-Lopez G, Graña O, Rubio-Camarillo M, Martinez-Martí A, Yokota J, Carretero J, Galbis JM, Nadal E, Pisano D, Sozzi G, Felip E, Montuenga LM, Roz L, Villanueva A, Sanchez-Cespedes M.

Clin Cancer Res. 2017 Jun 15;23(12):3203-3213. doi: 10.1158/1078-0432.CCR-16-1946. Epub 2017 Mar 16.

14.

A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis.

Ajona D, Ortiz-Espinosa S, Moreno H, Lozano T, Pajares MJ, Agorreta J, Bértolo C, Lasarte JJ, Vicent S, Hoehlig K, Vater A, Lecanda F, Montuenga LM, Pio R.

Cancer Discov. 2017 Jul;7(7):694-703. doi: 10.1158/2159-8290.CD-16-1184. Epub 2017 Mar 13.

15.

Strategies to design clinical studies to identify predictive biomarkers in cancer research.

Perez-Gracia JL, Sanmamed MF, Bosch A, Patiño-Garcia A, Schalper KA, Segura V, Bellmunt J, Tabernero J, Sweeney CJ, Choueiri TK, Martín M, Fusco JP, Rodriguez-Ruiz ME, Calvo A, Prior C, Paz-Ares L, Pio R, Gonzalez-Billalabeitia E, Gonzalez Hernandez A, Páez D, Piulats JM, Gurpide A, Andueza M, de Velasco G, Pazo R, Grande E, Nicolas P, Abad-Santos F, Garcia-Donas J, Castellano D, Pajares MJ, Suarez C, Colomer R, Montuenga LM, Melero I.

Cancer Treat Rev. 2017 Feb;53:79-97. doi: 10.1016/j.ctrv.2016.12.005. Epub 2016 Dec 30. Review.

16.

Telomere length, COPD and emphysema as risk factors for lung cancer.

de-Torres JP, Sanchez-Salcedo P, Bastarrika G, Alcaide AB, Pío R, Pajares MJ, Campo A, Berto J, Montuenga L, Del Mar Ocon M, Monente C, Celli BR, Zulueta JJ.

Eur Respir J. 2017 Jan 3;49(1). pii: 1601521. doi: 10.1183/13993003.01521-2016. Print 2017 Jan. No abstract available.

17.

Targeted depletion of PIK3R2 induces regression of lung squamous cell carcinoma.

Vallejo-Díaz J, Olazabal-Morán M, Cariaga-Martínez AE, Pajares MJ, Flores JM, Pio R, Montuenga LM, Carrera AC.

Oncotarget. 2016 Dec 20;7(51):85063-85078. doi: 10.18632/oncotarget.13195.

18.

A large-scale analysis of alternative splicing reveals a key role of QKI in lung cancer.

de Miguel FJ, Pajares MJ, Martínez-Terroba E, Ajona D, Morales X, Sharma RD, Pardo FJ, Rouzaut A, Rubio A, Montuenga LM, Pio R.

Mol Oncol. 2016 Nov;10(9):1437-1449. doi: 10.1016/j.molonc.2016.08.001. Epub 2016 Aug 9.

19.

Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.

Alegre E, Fusco JP, Restituto P, Salas-Benito D, Rodríguez-Ruiz ME, Andueza MP, Pajares MJ, Patiño-García A, Pio R, Lozano MD, Gúrpide A, Lopez-Picazo JM, Gil-Bazo I, Perez-Gracia JL, Gonzalez A.

Tumour Biol. 2016 Oct;37(10):13687-13694. Epub 2016 Jul 29.

PMID:
27473086
20.

Epigenetic alterations leading to TMPRSS4 promoter hypomethylation and protein overexpression predict poor prognosis in squamous lung cancer patients.

Villalba M, Diaz-Lagares A, Redrado M, de Aberasturi AL, Segura V, Bodegas ME, Pajares MJ, Pio R, Freire J, Gomez-Roman J, Montuenga LM, Esteller M, Sandoval J, Calvo A.

Oncotarget. 2016 Apr 19;7(16):22752-69. doi: 10.18632/oncotarget.8045.

21.

A Novel Epigenetic Signature for Early Diagnosis in Lung Cancer.

Diaz-Lagares A, Mendez-Gonzalez J, Hervas D, Saigi M, Pajares MJ, Garcia D, Crujerias AB, Pio R, Montuenga LM, Zulueta J, Nadal E, Rosell A, Esteller M, Sandoval J.

Clin Cancer Res. 2016 Jul 1;22(13):3361-71. doi: 10.1158/1078-0432.CCR-15-2346. Epub 2016 Feb 3.

22.

TMPRSS4 induces cancer stem cell-like properties in lung cancer cells and correlates with ALDH expression in NSCLC patients.

de Aberasturi AL, Redrado M, Villalba M, Larzabal L, Pajares MJ, Garcia J, Evans SR, Garcia-Ros D, Bodegas ME, Lopez L, Montuenga L, Calvo A.

Cancer Lett. 2016 Jan 28;370(2):165-76. doi: 10.1016/j.canlet.2015.10.012. Epub 2015 Nov 4.

PMID:
26546046
23.

Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations.

Aramburu A, Zudaire I, Pajares MJ, Agorreta J, Orta A, Lozano MD, Gúrpide A, Gómez-Román J, Martinez-Climent JA, Jassem J, Skrzypski M, Suraokar M, Behrens C, Wistuba II, Pio R, Rubio A, Montuenga LM.

BMC Genomics. 2015 Oct 6;16:752. doi: 10.1186/s12864-015-1935-0.

24.

Complement activation product C4d in oral and oropharyngeal squamous cell carcinoma.

Ajona D, Pajares MJ, Chiara MD, Rodrigo JP, Jantus-Lewintre E, Camps C, Suarez C, Bagán JV, Montuenga LM, Pio R.

Oral Dis. 2015 Oct;21(7):899-904. doi: 10.1111/odi.12363. Epub 2015 Sep 7.

PMID:
26258989
25.

Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators.

Rakha E, Pajares MJ, Ilie M, Pio R, Echeveste J, Hughes E, Soomro I, Long E, Idoate MA, Wagner S, Lanchbury JS, Baldwin DR, Hofman P, Montuenga LM.

Eur J Cancer. 2015 Sep;51(14):1897-903. doi: 10.1016/j.ejca.2015.07.015. Epub 2015 Jul 30.

PMID:
26235745
26.

Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients.

Grbesa I, Pajares MJ, Martínez-Terroba E, Agorreta J, Mikecin AM, Larráyoz M, Idoate MA, Gall-Troselj K, Pio R, Montuenga LM.

PLoS One. 2015 Apr 27;10(4):e0124670. doi: 10.1371/journal.pone.0124670. eCollection 2015.

27.

Elevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer.

Ajona D, Razquin C, Pastor MD, Pajares MJ, Garcia J, Cardenal F, Fleischhacker M, Lozano MD, Zulueta JJ, Schmidt B, Nadal E, Paz-Ares L, Montuenga LM, Pio R.

PLoS One. 2015 Mar 23;10(3):e0119878. doi: 10.1371/journal.pone.0119878. eCollection 2015.

28.

Improving selection criteria for lung cancer screening. The potential role of emphysema.

Sanchez-Salcedo P, Wilson DO, de-Torres JP, Weissfeld JL, Berto J, Campo A, Alcaide AB, Pueyo J, Bastarrika G, Seijo LM, Pajares MJ, Pio R, Montuenga LM, Zulueta JJ.

Am J Respir Crit Care Med. 2015 Apr 15;191(8):924-31. doi: 10.1164/rccm.201410-1848OC.

29.

Lung cancer screening: fourteen year experience of the Pamplona early detection program (P-IELCAP).

Sanchez-Salcedo P, Berto J, de-Torres JP, Campo A, Alcaide AB, Bastarrika G, Pueyo JC, Villanueva A, Echeveste JI, Lozano MD, García-Velloso MJ, Seijo LM, García J, Torre W, Pajares MJ, Pío R, Montuenga LM, Zulueta JJ.

Arch Bronconeumol. 2015 Apr;51(4):169-76. doi: 10.1016/j.arbres.2014.09.019. Epub 2015 Jan 29. English, Spanish.

30.

Phosphoinositide 3-kinase p85beta regulates invadopodium formation.

Cariaga-Martínez AE, Cortés I, García E, Pérez-García V, Pajares MJ, Idoate MA, Redondo-Muñóz J, Antón IM, Carrera AC.

Biol Open. 2014 Sep 12;3(10):924-36. doi: 10.1242/bio.20148185.

31.

TRAP1 regulates proliferation, mitochondrial function, and has prognostic significance in NSCLC.

Agorreta J, Hu J, Liu D, Delia D, Turley H, Ferguson DJ, Iborra F, Pajares MJ, Larrayoz M, Zudaire I, Pio R, Montuenga LM, Harris AL, Gatter K, Pezzella F.

Mol Cancer Res. 2014 May;12(5):660-9. doi: 10.1158/1541-7786.MCR-13-0481. Epub 2014 Feb 24.

32.

Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype.

Larrayoz M, Pio R, Pajares MJ, Zudaire I, Ajona D, Casanovas O, Montuenga LM, Agorreta J.

EMBO Mol Med. 2014 Apr;6(4):539-50. doi: 10.1002/emmm.201303214. Epub 2014 Feb 5.

33.

TGFBI expression is an independent predictor of survival in adjuvant-treated lung squamous cell carcinoma patients.

Pajares MJ, Agorreta J, Salvo E, Behrens C, Wistuba II, Montuenga LM, Pio R, Rouzaut A.

Br J Cancer. 2014 Mar 18;110(6):1545-51. doi: 10.1038/bjc.2014.33. Epub 2014 Jan 30.

34.

New syngeneic inflammatory-related lung cancer metastatic model harboring double KRAS/WWOX alterations.

Bleau AM, Freire J, Pajares MJ, Zudaire I, Anton I, Nistal-Villán E, Redrado M, Zandueta CN, Garmendia I, Ajona D, Blanco D, Pio R, Lecanda F, Calvo A, Montuenga LM.

Int J Cancer. 2014 Dec 1;135(11):2516-27. doi: 10.1002/ijc.28574. Epub 2014 Jan 28.

35.

Identification of alternative splicing events regulated by the oncogenic factor SRSF1 in lung cancer.

de Miguel FJ, Sharma RD, Pajares MJ, Montuenga LM, Rubio A, Pio R.

Cancer Res. 2014 Feb 15;74(4):1105-15. doi: 10.1158/0008-5472.CAN-13-1481. Epub 2013 Dec 26.

36.

RHOB influences lung adenocarcinoma metastasis and resistance in a host-sensitive manner.

Luis-Ravelo D, Antón I, Zandueta C, Valencia K, Pajares MJ, Agorreta J, Montuenga L, Vicent S, Wistuba II, De Las Rivas J, Lecanda F.

Mol Oncol. 2014 Mar;8(2):196-206. doi: 10.1016/j.molonc.2013.11.001. Epub 2013 Nov 12.

37.

A prognostic DNA methylation signature for stage I non-small-cell lung cancer.

Sandoval J, Mendez-Gonzalez J, Nadal E, Chen G, Carmona FJ, Sayols S, Moran S, Heyn H, Vizoso M, Gomez A, Sanchez-Cespedes M, Assenov Y, Müller F, Bock C, Taron M, Mora J, Muscarella LA, Liloglou T, Davies M, Pollan M, Pajares MJ, Torre W, Montuenga LM, Brambilla E, Field JK, Roz L, Lo Iacono M, Scagliotti GV, Rosell R, Beer DG, Esteller M.

J Clin Oncol. 2013 Nov 10;31(32):4140-7. doi: 10.1200/JCO.2012.48.5516. Epub 2013 Sep 30.

38.

Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer.

Ajona D, Pajares MJ, Corrales L, Perez-Gracia JL, Agorreta J, Lozano MD, Torre W, Massion PP, de-Torres JP, Jantus-Lewintre E, Camps C, Zulueta JJ, Montuenga LM, Pio R.

J Natl Cancer Inst. 2013 Sep 18;105(18):1385-93. doi: 10.1093/jnci/djt205. Epub 2013 Aug 12.

39.

Smokers with CT detected emphysema and no airway obstruction have decreased plasma levels of EGF, IL-15, IL-8 and IL-1ra.

de-Torres JP, Blanco D, Alcaide AB, Seijo LM, Bastarrika G, Pajares MJ, Muñoz-Barrutia A, Ortiz-de-Solorzano C, Pio R, Campo A, Montes U, Segura V, Pueyo J, Montuenga LM, Zulueta JJ.

PLoS One. 2013;8(4):e60260. doi: 10.1371/journal.pone.0060260. Epub 2013 Apr 5.

40.

Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression.

Corrales L, Ajona D, Rafail S, Lasarte JJ, Riezu-Boj JI, Lambris JD, Rouzaut A, Pajares MJ, Montuenga LM, Pio R.

J Immunol. 2012 Nov 1;189(9):4674-83. doi: 10.4049/jimmunol.1201654. Epub 2012 Oct 1.

41.

Phosphorylated tubulin adaptor protein CRMP-2 as prognostic marker and candidate therapeutic target for NSCLC.

Oliemuller E, Peláez R, Garasa S, Pajares MJ, Agorreta J, Pío R, Montuenga LM, Teijeira A, Llanos S, Rouzaut A.

Int J Cancer. 2013 May 1;132(9):1986-95. doi: 10.1002/ijc.27881. Epub 2012 Oct 20.

42.

Identification of novel deregulated RNA metabolism-related genes in non-small cell lung cancer.

Valles I, Pajares MJ, Segura V, Guruceaga E, Gomez-Roman J, Blanco D, Tamura A, Montuenga LM, Pio R.

PLoS One. 2012;7(8):e42086. doi: 10.1371/journal.pone.0042086. Epub 2012 Aug 2.

43.

Receptor of activated protein C promotes metastasis and correlates with clinical outcome in lung adenocarcinoma.

Antón I, Molina E, Luis-Ravelo D, Zandueta C, Valencia K, Ormazabal C, Martínez-Canarias S, Perurena N, Pajares MJ, Agorreta J, Montuenga LM, Segura V, Wistuba II, De Las Rivas J, Hermida J, Lecanda F.

Am J Respir Crit Care Med. 2012 Jul 1;186(1):96-105. doi: 10.1164/rccm.201110-1826OC. Epub 2012 Mar 29.

44.

Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung.

Pajares MJ, Agorreta J, Larrayoz M, Vesin A, Ezponda T, Zudaire I, Torre W, Lozano MD, Brambilla E, Brambilla C, Wistuba II, Behrens C, Timsit JF, Pio R, Field JK, Montuenga LM.

J Clin Oncol. 2012 Apr 1;30(10):1129-36. doi: 10.1200/JCO.2011.37.4231. Epub 2012 Feb 21.

45.

Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) reduces cell survival, homing, and colonization in lung cancer bone metastasis.

Valencia K, Ormazábal C, Zandueta C, Luis-Ravelo D, Antón I, Pajares MJ, Agorreta J, Montuenga LM, Martínez-Canarias S, Leitinger B, Lecanda F.

Clin Cancer Res. 2012 Feb 15;18(4):969-80. doi: 10.1158/1078-0432.CCR-11-1686. Epub 2012 Jan 5.

46.

Overexpression of TMPRSS4 in non-small cell lung cancer is associated with poor prognosis in patients with squamous histology.

Larzabal L, Nguewa PA, Pio R, Blanco D, Sanchez B, Rodríguez MJ, Pajares MJ, Catena R, Montuenga LM, Calvo A.

Br J Cancer. 2011 Nov 8;105(10):1608-14. doi: 10.1038/bjc.2011.432.

47.

Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance.

Ponz-Sarvisé M, Nguewa PA, Pajares MJ, Agorreta J, Lozano MD, Redrado M, Pio R, Behrens C, Wistuba II, García-Franco CE, García-Foncillas J, Montuenga LM, Calvo A, Gil-Bazo I.

Clin Cancer Res. 2011 Jun 15;17(12):4155-66. doi: 10.1158/1078-0432.CCR-10-3381. Epub 2011 May 3.

48.

Complement factor H is elevated in bronchoalveolar lavage fluid and sputum from patients with lung cancer.

Pio R, Garcia J, Corrales L, Ajona D, Fleischhacker M, Pajares MJ, Cardenal F, Seijo L, Zulueta JJ, Nadal E, Witt C, Lozano MD, Schmidt B, Montuenga LM.

Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2665-72. doi: 10.1158/1055-9965.EPI-10-0467. Epub 2010 Aug 27.

49.

The oncoprotein SF2/ASF promotes non-small cell lung cancer survival by enhancing survivin expression.

Ezponda T, Pajares MJ, Agorreta J, Echeveste JI, López-Picazo JM, Torre W, Pio R, Montuenga LM.

Clin Cancer Res. 2010 Aug 15;16(16):4113-25. doi: 10.1158/1078-0432.CCR-10-0076. Epub 2010 Aug 3.

50.

Development of a novel splice array platform and its application in the identification of alternative splice variants in lung cancer.

Pio R, Blanco D, Pajares MJ, Aibar E, Durany O, Ezponda T, Agorreta J, Gomez-Roman J, Anton MA, Rubio A, Lozano MD, López-Picazo JM, Subirada F, Maes T, Montuenga LM.

BMC Genomics. 2010 Jun 3;11:352. doi: 10.1186/1471-2164-11-352.

Supplemental Content

Loading ...
Support Center